Insmed Incorporated (NASDAQ:INSM) Shares Bought by Legato Capital Management LLC

Legato Capital Management LLC grew its position in Insmed Incorporated (NASDAQ:INSM) by 2.2% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 36,871 shares of the biopharmaceutical company’s stock after acquiring an additional 792 shares during the quarter. Legato Capital Management LLC’s holdings in Insmed were worth $2,546,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. CIBC Asset Management Inc boosted its stake in Insmed by 3.5% during the 3rd quarter. CIBC Asset Management Inc now owns 4,438 shares of the biopharmaceutical company’s stock worth $324,000 after purchasing an additional 149 shares during the period. Abel Hall LLC raised its position in Insmed by 4.7% during the 4th quarter. Abel Hall LLC now owns 3,333 shares of the biopharmaceutical company’s stock worth $230,000 after buying an additional 151 shares during the last quarter. Commerce Bank lifted its stake in shares of Insmed by 2.4% in the 3rd quarter. Commerce Bank now owns 6,833 shares of the biopharmaceutical company’s stock worth $499,000 after acquiring an additional 163 shares during the period. Nisa Investment Advisors LLC boosted its holdings in shares of Insmed by 5.5% in the fourth quarter. Nisa Investment Advisors LLC now owns 3,533 shares of the biopharmaceutical company’s stock valued at $244,000 after acquiring an additional 183 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Insmed by 3.0% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,401 shares of the biopharmaceutical company’s stock worth $446,000 after acquiring an additional 186 shares during the period.

Analysts Set New Price Targets

A number of brokerages recently commented on INSM. Morgan Stanley raised their price objective on shares of Insmed from $85.00 to $90.00 and gave the company an “overweight” rating in a research report on Thursday, February 6th. Guggenheim lifted their price target on Insmed from $95.00 to $101.00 and gave the company a “buy” rating in a research note on Friday, February 7th. Stifel Nicolaus increased their price objective on Insmed from $88.00 to $97.00 and gave the stock a “buy” rating in a research report on Tuesday. Truist Financial restated a “buy” rating and set a $105.00 target price (up from $100.00) on shares of Insmed in a research report on Friday, November 1st. Finally, HC Wainwright reiterated a “buy” rating and issued a $90.00 price target on shares of Insmed in a report on Friday, November 1st. One investment analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $85.60.

Insider Transactions at Insmed

In related news, insider Orlov S. Nicole Schaeffer sold 91,140 shares of the firm’s stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $80.00, for a total transaction of $7,291,200.00. Following the sale, the insider now owns 97,083 shares in the company, valued at approximately $7,766,640. This trade represents a 48.42 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Martina M.D. Flammer sold 33,055 shares of the business’s stock in a transaction on Thursday, February 6th. The shares were sold at an average price of $80.90, for a total value of $2,674,149.50. Following the completion of the transaction, the insider now owns 138,053 shares of the company’s stock, valued at $11,168,487.70. This trade represents a 19.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 401,030 shares of company stock valued at $30,993,629 over the last three months. 4.60% of the stock is currently owned by insiders.

Insmed Stock Up 2.3 %

Shares of Insmed stock opened at $79.89 on Wednesday. Insmed Incorporated has a 1 year low of $21.92 and a 1 year high of $82.04. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37. The business has a 50 day moving average price of $73.00 and a 200 day moving average price of $73.12.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.